明德生物(002932) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥60,963,422.30, a decrease of 83.63% compared to ¥372,402,234.89 in the same period last year[3] - Net profit attributable to shareholders was ¥32,052,081.48, down 57.52% from ¥75,450,691.09 year-on-year[3] - The company reported a basic earnings per share of ¥0.14, a decline of 71.43% from ¥0.49 in the same period last year[3] - Total operating revenue for Q1 2024 was CNY 60,963,422.30, a decrease of 83.7% compared to CNY 372,402,234.89 in the same period last year[16] - Net profit for Q1 2024 was CNY 28,108,162.20, a decline of 65.5% compared to CNY 81,455,808.44 in Q1 2023[17] - Earnings per share for Q1 2024 were CNY 0.14, down from CNY 0.49 in the same quarter last year[18] Cash Flow - The net cash flow from operating activities improved to ¥45,688,082.68, a significant increase of 113.39% compared to a negative cash flow of -¥341,182,026.20 in the previous year[3] - Cash inflow from operating activities was CNY 294,315,194.08, a decrease of 28.2% from CNY 410,773,725.79 in the previous year[19] - The net cash flow from operating activities for Q1 2024 was ¥45,688,082.68, a significant improvement compared to the net cash outflow of ¥341,182,026.20 in the same period last year[20] - The company reported a total cash outflow from operating activities of ¥248,627,111.40 in Q1 2024, compared to ¥751,955,751.99 in the previous year, showing improved cash management[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,240,838,105.70, a decrease of 1.97% from ¥7,386,599,894.20 at the end of the previous year[3] - The total liabilities decreased from ¥1,019,362,336.64 to ¥858,191,366.70, indicating a reduction in current liabilities[13] - The total assets of the company are ¥7,240,838,105.70, down from ¥7,386,599,894.20[13] - The total liabilities decreased to CNY 932,938,163.48 from CNY 1,094,498,430.83, indicating a reduction of 14.8%[17] Investments and Expenses - The company’s research and development expenses were ¥27,181,929.06, down 18.09% from ¥33,184,792.04 in the previous year[8] - Research and development expenses for Q1 2024 were CNY 27,181,929.06, down 18.1% from CNY 33,184,792.04 in Q1 2023[17] - The company’s investment income increased by 20.82% to ¥26,856,887.97 compared to ¥22,229,018.90 in the previous year[8] - Sales expenses decreased to CNY 24,076,564.00, a reduction of 47.6% compared to CNY 45,958,031.73 in the previous year[17] - Management expenses were CNY 18,843,544.05, down 33.1% from CNY 28,131,259.82 year-over-year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,071[10] - The largest shareholder, Chen Lili, holds 27.06% of the shares, totaling 62,918,895 shares[10] - The company has no preferred shareholders as of the reporting period[11] Cash and Cash Equivalents - The cash and cash equivalents at the end of the period are ¥985,872,470.91, down from ¥1,015,682,930.54[12] - The total cash and cash equivalents at the end of Q1 2024 stood at ¥884,229,415.35, down from ¥3,196,431,442.74 at the end of Q1 2023[20] Other Financial Metrics - The company’s short-term borrowings decreased by 87.30% to ¥3,000,000.00 from ¥23,614,136.50 in the previous year[8] - The company’s cash flow from investing activities was -¥60,596,877.14, a decrease of 106.29% compared to ¥962,712,215.42 in the previous year[9] - Total cash outflow from investing activities was ¥66,088,150.65, compared to ¥1,003,522,693.89 in Q1 2023, indicating a reduction in investment expenditures[20] - The company experienced a negative impact of ¥376,414.61 from exchange rate fluctuations on cash and cash equivalents[20] Accounting and Audit - The company did not conduct an audit for the Q1 2024 report, which may affect the perception of financial reliability[22] - The company has not adopted the new accounting standards for the current year, which may impact future financial reporting[21]